Condition

Non-alcoholic Steatohepatitis clinical trials and research

• 14Clinical trials
• 20NIH research projects
• 8Countries

Newest Non-alcoholic Steatohepatitis clinical trials

All recruiting trials (14)

• HEC169584 capsule safety and how the body processes it in healthy adults

  This trial will test the safety, tolerability, and how the body absorbs and processes HEC169584 capsules in healthy adults aged 18–45.

  Recruiting Phase 1 Sunshine Lake Pharma Co., Ltd. · Beijing, Beijing Municipality · NCT07099118

• Blood markers to detect liver scarring in fatty liver disease

  This will test whether blood markers can detect liver scarring in adults with NAFLD or NASH who are having or recently had a liver biopsy.

  Recruiting at 2 sites Roche Diagnostics GmbH · Copenhagen and 1 other locations · NCT06819917

• Evaluating a new treatment for Non-alcoholic Steatohepatitis

  This study is testing a new treatment for Non-alcoholic Steatohepatitis (NASH) to see if it can improve liver health in adults.

  Recruiting Phase 2 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Lu'an, Anhui and 52 other locations · NCT06569524

• Endoscopic sleeve gastroplasty for people with obesity and MASH

  This study will test whether endoscopic sleeve gastroplasty plus lifestyle changes helps adults with obesity and MASH lose weight and improve liver health compared with lifestyle changes alone.

  Recruiting at 2 sites Brigham and Women's Hospital · Boston, Massachusetts and 1 other locations · NCT06138821

• Using endoscopic ultrasound to assess liver stiffness in patients with fatty liver disease

  This study is testing if a special ultrasound can help find liver damage in people with fatty liver disease who are overweight, comparing it to other methods to see which works best.

  Recruiting at 2 sites Brigham and Women's Hospital · Boston, Massachusetts and 1 other locations · NCT05728697

• Understanding liver disease linked to alcohol and metabolic syndrome

  This study is trying to find out what causes liver cancer in people with alcohol-related liver disease and fatty liver disease by looking at their health, diet, and immune system over several years.

  Recruiting Institut National de la Santé Et de la Recherche Médicale, France · Nice · NCT05623150

• Effect of a fibre supplement on children with fatty liver disease

  This study is testing whether a fiber supplement can help children aged 8-17 with fatty liver disease improve their liver health over six months.

  Recruiting Phase 2 McMaster University · Hamilton, Ontario · NCT05480696

• Collecting data to predict cancer risk in at-risk populations

  This study is trying to collect samples and health information from people at higher risk of cancer to see if they can find signs that help predict cancer early on.

  Recruiting Dana-Farber Cancer Institute · Boston, Massachusetts · NCT05463796

• Creating biological models to study liver diseases and tumors

  This study is trying to create new models to better understand liver diseases and tumors so that we can find better treatments for people suffering from these conditions.

  Recruiting Institut National de la Santé Et de la Recherche Médicale, France · Strasbourg · NCT04690972

• Improving early diagnosis of liver disease using integrated diagnostics

  This study is trying to improve how quickly and accurately liver disease is diagnosed by combining different tests and information from around 750 patients who are at risk or have abnormal liver blood tests.

  Recruiting Manchester University NHS Foundation Trust · Manchester, Greater Manchester · NCT04666402

• Assessing the prevalence of Non-Alcoholic Fatty Liver Disease in adults

  This study is trying to find out how common Non-Alcoholic Fatty Liver Disease is among adults in Olmsted County, Minnesota, to help improve early diagnosis and treatment options.

  Recruiting Mayo Clinic · Rochester, Minnesota · NCT04365855

• Registry for children with Non-Alcoholic Fatty Liver Disease in Europe

  This study is creating a large registry to help doctors learn more about Non-Alcoholic Fatty Liver Disease in children and improve future treatments.

  Recruiting at 2 sites Cambridge University Hospitals NHS Foundation Trust · Maastricht and 2 other locations · NCT04190849

• Understanding liver response to glucose and the effects of semaglutide in fatty liver disease

  This study is testing how the liver of people with non-alcoholic fatty liver disease responds to food and whether the medication semaglutide can help improve liver health.

  Recruiting Phase 2 National Institutes of Health Clinical Center (CC) · Bethesda, Maryland · NCT03884075

• Examining the impact of fatty liver disease in bariatric patients

  This study is trying to see how non-alcoholic fatty liver disease affects health outcomes in people with obesity who are having bariatric surgery compared to those who aren't.

  Recruiting Esbjerg Hospital - University Hospital of Southern Denmark · Esbjerg · NCT03535142

NIH-funded research (20)

Early-stage science funded by the US National Institutes of Health. Most of these projects don't enroll patients, but they show what is being worked on.

• Role of metabolic stress in NASH-related liver cancer

  This grant explores how metabolic stress linked to NASH may drive liver cancer and looks for ways to interrupt that process to help patients.

  NIH research Sanford Burnham Prebys Medical Discovery Institute · La Jolla, United States · NIH-11418957

• TREM2: a helper in liver inflammation and scarring in NASH

  A new approach studies how a liver immune receptor called TREM2 helps protect against liver inflammation and scarring in people with fatty liver disease that can progress to NASH.

  NIH research Sanford Burnham Prebys Medical Discovery Institute · La Jolla, United States · NIH-11372278

• Genes behind fatty liver disease and NASH

  This project looks at how specific genes change fatty liver disease and scarring to help guide better tests and treatments for people with NAFLD/NASH.

  NIH research University of California Los Angeles · Los Angeles, United States · NIH-11333754

• Ex-vivo bioengineered liver cells to study NASH-related dysfunction

  Researchers will use patient-derived stem cell–made liver cells in a lab setup to understand why NASH causes liver damage and how stiffness of the liver’s surroundings affects this process.

  NIH research University of Arizona · Tucson, United States · NIH-11324204

• How TREM2 on immune cells affects fatty liver disease (NASH)

  This project looks at whether the immune protein TREM2 helps drive liver inflammation and scarring in people with NASH.

  NIH research Ut Southwestern Medical Center · Dallas, United States · NIH-11261177

• New small-molecule medicines that stabilize Axin to treat non-alcoholic steatohepatitis (NASH)

  Trying new small-molecule drugs that stabilize Axin to lower liver fat and scarring for people with NASH.

  NIH research University of Maryland Baltimore · Baltimore, United States · NIH-11261165

• How bile acids and sphingosine-1-phosphate affect fatty liver (NASH)

  This project looks at how bile acids and a fat-signaling molecule called sphingosine-1-phosphate change liver cells in people with NASH to find new treatment leads.

  NIH research VA Veterans Administration Hospital · Richmond, United States · NIH-11212757

• How overeating and metabolic stress drive NASH-related liver cancer

  This research looks at how excess nutrition and cell stress change liver metabolism and push NASH (fatty liver disease) toward liver cancer, with the goal of finding points to stop that process.

  NIH research Sanford Burnham Prebys Medical Discovery Institute · La Jolla, United States · NIH-11189737

• Understanding how a protein called TREM2 affects non-alcoholic steatohepatitis (NASH)

  This project explores how a protective protein called TREM2 works inside and outside liver cells to help prevent the progression of non-alcoholic steatohepatitis, a serious liver condition.

  NIH research Sanford Burnham Prebys Medical Discovery Institute · La Jolla, United States · NIH-11176076

• Understanding the role of TREM2 in liver disease progression.

  This study is looking at how a protein called TREM2 affects the liver condition known as non-alcoholic steatohepatitis (NASH) to help understand why some people with fatty liver get worse while others don’t, with the hope of finding new ways to treat NASH.

  NIH research Sanford Burnham Prebys Medical Discovery Institute · La Jolla, United States · NIH-11128281

• Understanding the genetics of non-alcoholic fatty liver disease

  This study is looking at non-alcoholic fatty liver disease (NAFLD) to understand how our genes and environment work together to affect liver health, with the hope of finding better ways to diagnose and treat this condition for people who have it.

  NIH research University of California Los Angeles · Los Angeles, United States · NIH-11086834

• Investigating liver dysfunction caused by non-alcoholic steatohepatitis using bioengineered technology

  This study is looking at a serious liver condition called NASH by taking blood from patients and turning it into liver-like cells to better understand how the disease works and find new ways to treat it.

  NIH research University of Arizona · Tucson, United States · NIH-11085912

• Understanding how the unfolded protein response affects liver disease

  This study is looking at how a protective process in the liver, called the unfolded protein response, is lost in people with non-alcoholic steatohepatitis (NASH), and it aims to find ways to help restore this process to prevent liver damage.

  NIH research Massachusetts General Hospital · Boston, United States · NIH-11054379

• Understanding how TREM2 affects liver disease related to obesity

  This study is looking at how a certain receptor called TREM2 affects liver inflammation and damage in people with nonalcoholic steatohepatitis (NASH), a serious liver condition often related to obesity, to help us understand more about what causes this disease and how it might be treated.

  NIH research Ut Southwestern Medical Center · Dallas, United States · NIH-11013386

• Using new small molecules to stabilize Axin for treating liver disease

  This study is looking at new small molecules that could help improve liver health for people with non-alcoholic steatohepatitis (NASH) by stabilizing a protein that helps manage liver metabolism and reducing fat buildup in the liver.

  NIH research University of Maryland Baltimore · Baltimore, United States · NIH-11012381

• Investigating bile acids and a specific signaling molecule in liver disease

  This study is looking at how certain substances in the body, like bile acids and sphingosine-1-phosphate, influence the worsening of non-alcoholic steatohepatitis (NASH), a serious liver condition, to help find new ways to treat it for people living with this disease.

  NIH research VA Veterans Administration Hospital · Richmond, United States · NIH-10950309

• Investigating how metabolic stress contributes to liver cancer development

  This study is looking at how extra weight and changes in metabolism might affect the growth of liver cancer in people with fatty liver disease, and it aims to find ways to slow down or prevent this cancer from getting worse.

  NIH research Sanford Burnham Prebys Medical Discovery Institute · La Jolla, United States · NIH-10935863

• Investigating a new drug to treat liver fibrosis caused by non-alcoholic steatohepatitis

  This study is looking at a new treatment called Oxy210 that might help people with non-alcoholic steatohepatitis (NASH) by reducing liver scarring and inflammation, and it’s designed to be taken easily by mouth.

  NIH research Max Biopharma, INC. · Los Angeles, United States · NIH-10832060

• Creating a new treatment for non-alcoholic steatohepatitis using a specialized antibody

  This study is testing a new treatment that uses a special type of antibody to help reduce liver inflammation and damage in people with non-alcoholic steatohepatitis (NASH), and it could offer a better option for managing the condition.

  NIH research Oncotrap, INC. · Chapel Hill, United States · NIH-10761039

• Improving treatments for non-alcoholic fatty liver disease

  This study is looking at new medications that could help people with obesity and type 2 diabetes by improving how their bodies handle insulin and sugar, which might also help reduce fat in the liver.

  NIH research Senseion Therapeutics, INC. · Saint Louis, United States · NIH-10461207

Related topics

Quick answers

How many Non-alcoholic Steatohepatitis clinical trials are recruiting right now?

14, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

In 8 countries. The most sites are in United States (5 trials), United Kingdom (2 trials), France (2 trials), Denmark (2 trials), China (2 trials). Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 2: 3, Phase 1: 1. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →